Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910637 · ClinicalTrials.gov registry record · Phase 3
Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,502
- Enrollment target
NCT00910637: Completed Phase 3 study, sponsored by Bayer.
NCT00910637 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,502 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910637, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,502 participants
- Enrollment target
Study Summary
This study is examining a birth control patch for 13 cycles (1 year).
Interventions
- DRUG Gestodene/EE Patch (BAY86-5016)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,502 participants |
| Start Date | 2009-05-01 |
| Est. Completion | 2010-12-13 |
| Phase | Phase 3 |
What the finished NCT00910637 record still lists
NCT00910637 is an interventional study that assigns participants to a tested intervention. Its 1,502 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 1 intervention - of which Gestodene/EE Patch (BAY86-5016) is the first listed.
NCT00910637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00910637 about?
NCT00910637 is a clinical study titled "Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles". This study is examining a birth control patch for 13 cycles (1 year).
What is the current status of trial NCT00910637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,502 participants. The study started on 2009-05-01. Estimated completion is 2010-12-13.
What interventions are being tested in trial NCT00910637?
The interventions under investigation include: Gestodene/EE Patch (BAY86-5016) (DRUG).
Who is sponsoring clinical trial NCT00910637?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00910637's enrollment target sits among peer trials
1,502 158th of 2000 higher than 1,843 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI